The third quarter was a breakthrough quarter for ODI Pharma AB (”ODI Pharma” or the ”Company”), with...
Tethys Oil står inför intressanta möjligheter trots utmaningar i Block 3&4.
Redeye updates its estimates on Artificial Solutions, which continues to grow strongly, underpinned ...
NOSIUM har levererat en solid inledning av år 2024, där Q1-rapporten visade på en minskad nettoomsät...
Dell storage and NetApp billings show improved momentum We estimate increased organic growth rates a...
Q-linea and its distribution partners continue to advance pilot and tender process activities, leadi...
Zoomability Int AB (”Zoomability” eller ”bolaget”) meddelade den 2 juni att bolagets konvertibla lån...
Lucky Games har publicerat bolagets delårsrapport för det första kvartalet år 2024 och visar på fort...
Despite lowering our short-term forecasts, Redeye retains its positive stance on Speqta following th...
IRLAB Therapeutics is swiftly progressing with the Phase I trial for IRL757, with the first particip...
Redeye updates its estimates and valuation following Freemelt’s Q1 report, which fell below expectat...
Redeye comments on the subscription price and the strong start of the Terclara launch.
Q1: sales SEK 0.82m, adj. EBIT -12m, no deliveries Q2 to be more eventful, SEK 12m of orders announc...
PTS has published new statistics for the SE fibre market BRE2 market share: slightly down versus 202...
Redeye comments on the positive outcome of Annexin’s rights issue.
